You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Drugs targeting plasma cells

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Multiple Myeloma in Remission Trial in Shenzhen, Haikou (MM-specific universal CAR T cells)

Recruiting
  • Multiple Myeloma in Remission
  • MM-specific universal CAR T cells
  • Shenzhen, Guangdong, China
  • +1 more
Aug 23, 2023

Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Phoenix (Autologous MUC1-activated T-cells,

Recruiting
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Phoenix, Arizona
    Mayo Clinic Hospital in Arizona
Jan 4, 2023

Multiple Myeloma, Immune System Diseases Trial in Chapel Hill (CAR138 T Cells)

Recruiting
  • Multiple Myeloma
  • Immune System Diseases
  • CAR138 T Cells
  • Chapel Hill, North Carolina
    Lineberger Comprehensive Cancer Center at University of North Ca
Jan 10, 2023

Relapsing Remitting Multiple Sclerosis, Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis Trial

Recruiting
  • Relapsing Remitting Multiple Sclerosis
  • +2 more
  • Ixazomib (NINLARO®) capsules / Matching placebo capsules
  • London, Greater London, United Kingdom
    Royal London Hospital, Barts Health NHS Foundation Trust
Feb 17, 2022

Multiple Myeloma Trial in Hangzhou (GPRC5D-CAR-T)

Recruiting
  • Multiple Myeloma
  • Hangzhou, Zhejiang, China
    The first affiliated hospital of medical college of zhejiang uni
Apr 12, 2022

Relapsed and/or Refractory Multiple Myeloma Trial in Köln (BMS-986453, Fludarabine, Cyclophosphamide)

Not yet recruiting
  • Relapsed and/or Refractory Multiple Myeloma
  • Köln, Germany
    Local Institution - 0017
Dec 4, 2023

Multiple Myeloma Trial (BMCA and GPRC5D dual target CAR-T cells(OriC321))

Not yet recruiting
  • Multiple Myeloma
  • BMCA and GPRC5D dual target CAR-T cells(OriC321)
  • (no location specified)
Apr 5, 2022

CS1+ or BCMA+ Multiple Myeloma Trial in Wuhan (Conditioning chemo followed by CAR T cell infusion)

Recruiting
  • CS1+ or BCMA+ Multiple Myeloma
  • Conditioning chemotherapy followed by CAR T cell infusion
  • Wuhan, Hubei, China
    Union Hospital, Tongji Medical College, Huazhong University of S
Feb 11, 2022

Safety and Efficacy Trial in Suzhou (anti-CD19 and anti-BCMA CAR, Immunomodulatory drugs)

Recruiting
  • Safety and Efficacy
  • anti-CD19 and anti-BCMA CAR
  • Immunomodulatory drugs
  • Suzhou, Jiangsu, China
    First Affiliated Hospital, Soochow University
May 17, 2021

Multiple Myeloma Trial in Shanghai (Anti-BCMA CAR-T cells, Fludarabine, Cyclophosphamide)

Recruiting
  • Multiple Myeloma
  • Anti-BCMA CAR-T cells
  • +3 more
  • Shanghai, Shanghai, China
    Shanghai Changzheng Hospital
Aug 29, 2021

Lymphoma, Myeloma, Leukemia Trial in Houston (Kappa CD28 T cells)

Recruiting
  • Lymphoma
  • +2 more
  • Kappa CD28 T cells
  • Houston, Texas
  • +1 more
Jan 31, 2022

Immunophenotyping of Plasma Cells and Immune Effector Cells in

Not yet recruiting
  • Multiple Myeloma
  • Biological sampling
  • (no location specified)
Jun 17, 2022

Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Duarte (CS1-CAR T Therapy, Cyclophosphamide, Fludarabine)

Recruiting
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • CS1-CAR T Therapy
  • +3 more
  • Duarte, California
    City of Hope Medical Center
Nov 15, 2021

Multiple Myeloma, Tumor, Plasma Cell, Tumors by Histologic Type Trial in United States (CYNK-001)

Active, not recruiting
  • Multiple Myeloma
  • +19 more
  • CYNK-001
  • Denver, Colorado
  • +8 more
May 24, 2022

Relapsed/Refractory Multiple Myeloma Trial in United States (UCARTCS1A)

Recruiting
  • Relapsed/Refractory Multiple Myeloma
  • UCARTCS1A
  • San Francisco, California
  • +4 more
Nov 11, 2021

Multiple Myeloma Trial in Taiyuan (CD19-CD22 CAR-T cells)

Recruiting
  • Multiple Myeloma
  • CD19-CD22 CAR-T cells
  • Taiyuan, Shanxi, China
    Hematology Department of ShanXi Cancer Hospital
Jan 17, 2021

Post Partum Hemorrhage, Fibrinogenolysis; Hemorrhage, Fibrinogen; Deficiency, Acquired Trial in Querétaro City (diagnostic test,

Completed
  • Post Partum Hemorrhage
  • +4 more
  • Thromboelastometry
  • +7 more
  • Querétaro City, Queretaro, Mexico
    Hospital de Especialidades Del Niño Y La Mujer
Jun 6, 2021

Multiple Myeloma Trial in Netherlands, United Kingdom (AUTO2)

Terminated
Has Results
  • Multiple Myeloma
  • AUTO2
  • Amsterdam, Netherlands
  • +3 more
Sep 30, 2020

Postoperative Pain Trial in Asyut (DEX-IV, DEX-Rectal, DEX-Nano-Rectal)

Recruiting
  • Postoperative Pain
  • Asyut, Assiut Governorate, Egypt
    South Egypt cancer institute, Assiut university
Jan 20, 2023

Newly Diagnosed Multiple Myeloma Trial in Germany (Isatuximab, Lenalidomide, Bortezomib)

Not yet recruiting
  • Newly Diagnosed Multiple Myeloma
  • Hamburg, Germany
  • +3 more
Dec 16, 2022

Nephrotic Syndrome Trial in Genova (Rituximab Biosimilar ABP 798, Daratumumab)

Not yet recruiting
  • Nephrotic Syndrome
  • Genova, Italy
    IRCCS G. Gaslini
Jan 19, 2023

Healthy Trial in Philadelphia (Blood draw)

Active, not recruiting
  • Healthy
  • Blood draw
  • Philadelphia, Pennsylvania
    The Clinical Translational Research Center (CTRC) at the Hospita
Aug 16, 2022

Platelet Membrane Cloaked Recombinant Staphylokinase on Human

Not yet recruiting
  • Arterial Thrombosis
  • collection of venous blood or arterial blood
  • (no location specified)
Aug 6, 2023

Pancreatic Cancer Trial in Shatin (MSLN CART)

Not yet recruiting
  • Pancreatic Cancer
  • MSLN CART
  • Shatin, N.t., Hong Kong
    Endoscopy Centre, Prince of Wales Hospital
Sep 19, 2023

HIV Trial in United States (ALVAC(2)120(B,MN)GNP (vCP1452))

Completed
  • HIV Infections
  • ALVAC(2)120(B,MN)GNP (vCP1452)
  • Birmingham, Alabama
  • +15 more
Oct 28, 2021